Bill Anderson doing the roadshow in Dc and Carlyle Group seems to be going in heavy at current levels or lower for the next RUN UP
a long game to make a killing for heavy hitters in the pharma bio agri chemical business the timing to position for such a deal takes time and feel in the this type of business
the usual play is Dress up Window PUMP for public retails the rest to participate unload shares and reserve cash to acquire a highly controversial company MONSANTO
ROUNUP herbicide with Glycophaste is the EYE SOAR or hang up where litigation is a downgrade for fund managers
it settled the 100,000 lawsuits on roundup to 11bn just this October 2023
this is done.. and we begin to DCA slowly and reserve at the buy zone or shakedown levels for next WINDOW DRESSING acquisition of BAYER
could be a COViD Vaccine or some super food enhance in the VEGiE MEAT business gaining traction
Note
Looks like Carlyle's DavidR takes over the float and must be putting in a team to bring back excitement with the stock
Note
massive shorts after that David Rubenstein interview. digested by big shots over the weekend..
Note
brutal reset ...
Note
exhaustion expedited SOLD out shares.. looks like $30 is the bottom loaded
Note
settlements and re org in progress..
Note
taking a position today with FED Powell giving a pre rate cut and settlement of Bayers case at work .. $27 zone +- 15% should be a good and decent base to build for FOOD SECURITY play in t he next 18 months with La Nina and El Nino phenomenon..
Note
Court Rejects claim.. great news for holders.. momentum to kick in. informed players took a gamble with a day green candle..
upsizing position for the greater come back
Note
freshly recovered with stabilization fund in place .. no more dumping looks ike SHORTS are covering before the next run up
Note
solid support .. tourist are gone LONG & STRONG
Note
nice and slow solid DISMISSAL of case catalyst.. just in time for FED RATE CUTSSSSSSS
Note
solid base building and rounded bottom of smart money
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.